• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is H.B. Fuller (FUL) Undervalued On Its $850 Million Debt Deal And AMS Acquisition?

    Simply Wall St·10/22/2026 21:34:35
    语音播报

    Debt deal reshapes H.B. Fuller’s capital structure

    H.B. Fuller (FUL) has completed an $850m private issue of 7.625% senior unsecured notes due 2034, a funding move tied to its pending Advanced Medical Solutions Group acquisition and to broader balance sheet refinancing.

    At a share price of $50.89, H.B. Fuller has seen its short-term momentum soften, with the 90-day share price return down 8.64% and the year-to-date share price return down 15.66%. The 1-year total shareholder return has declined 14.51%, pointing to fading enthusiasm even as this new debt issue and the pending Advanced Medical Solutions Group deal reshape expectations around growth potential and balance sheet risk.

    Spot opportunities beyond H.B. Fuller by scanning a hand-picked 32 high quality undervalued stocks that pairs balance sheet strength with potential mispricing.

    H.B. Fuller now pairs a softer share price record with a larger debt load and a pending medical adhesives deal. Is most of the upside already priced out, or does the current valuation still leave meaningful headroom?

    Most Popular Narrative: 25.5% Undervalued

    On the most followed narrative, H.B. Fuller’s fair value of $68.29 sits well above the recent $50.89 share price. As a result, the gap between execution on its medical and margin plans and current sentiment is front and center.

    The acquisition of ND Industries and restructuring benefits are now joined by the pending AMS acquisition and the performance of prior medical deals such as GEM and Medifill. The enlarged medical platform is expected to reach roughly 10% of revenue and support EBITDA margins above 30% in that segment by 2030, which would contribute to higher consolidated revenue, margins and earnings.

    See why 2 investors see H.B. Fuller as 25% undervalued.

    Result: Fair Value of $68.29 (UNDERVALUED)

    Still, this H.B. Fuller narrative can be knocked off course if AMS integration drags on cash flow or if petrochemical costs jump faster than pricing can absorb.

    Find out about the key risks to this H.B. Fuller narrative.

    Next Steps

    Mixed signals around H.B. Fuller’s debt, medical exposure and valuation only matter if you test them against the full picture yourself, so move quickly to weigh up both sides through the 6 key rewards and 1 important warning sign.

    Looking for more H.B. Fuller investment ideas?

    If you stop with H.B. Fuller, you could miss other stocks that better fit your goals, so put the Simply Wall Street Screener to work.